Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors

EGFR exon 20 insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib, and osimertinib, and the heterogeneity of EGFR e20ins further com...

ver descrição completa

Detalhes bibliográficos

Principais autores:	YanRu Qin, Hong Jian, Xiaoling Tong, Xue Wu, Fufeng Wang, Yang W. Shao, Xinmin Zhao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-08-01
coleção:	Molecular Oncology
Assuntos:	EGFR exon 20 insertion lung cancer osimertinib poziotinib tyrosine kinase inhibitor
Acesso em linha:	https://doi.org/10.1002/1878-0261.12710
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!